SCARA5

Across TCGA pan-cancer cohorts, SCARA5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SCARA5 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SCARA5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SCARA5 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where SCARA5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.231	0.911	.038	20	view →
HNSC	OS	Tertile	IV	0.960	0.559	.004	19	view →
LUAD	DFS	Tertile	III,IV	0.721	1.000	.016	8	view →
LSCC	DFS	Quartile	II,III,IV	0.804	0.938	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SCARA5–PDAC (OS)

Open the PDAC breakdown →